16 completed, 3 unknown, 1 terminated, 1 withdrawn. 12 Phase 2, 10 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Completed 8, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 10 | Completed 8, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
Follow ASLAN Pharmaceuticals: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants Farudodstat, Placebo - Alopecia Areata | Phase 2 | Unknown | ASLAN Pharmaceuticals | 60 | 2023-04-14 | 2023-12-18 |
| Study of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab Placebo, ASLAN004 - Atopic Dermatitis | Phase 2 | Unknown | ASLAN Pharmaceuticals | 75 | 2022-12-21 | 2024-01-18 |
| Phase 2b Study of ASLAN004 in Adults With Moderate-to-Severe Atopic Dermatitis Placebo Comparator, ASLAN004 - Atopic Dermatitis | Phase 2 | Completed | ASLAN Pharmaceuticals | 302 | 2022-03-16 | 2024-04-26 |
| A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis ASLAN004, ASLAN004 Placebo - Atopic Dermatitis | Phase 1 | Completed | ASLAN Pharmaceuticals | 52 | 2019-09-09 | 2022-01-12 |
| Study of ASLAN004 in Healthy Subjects ASLAN004 - Allergic Disorder | Phase 1 | Completed | ASLAN Pharmaceuticals | 44 | 2018-10-15 | 2020-08-05 |
| Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine - Advanced or Metastatic Biliary Tract Cancer | Phase 2 | Withdrawn | ASLAN Pharmaceuticals | 2018-05-01 | 2018-05-23 | |
| A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia ASLAN003 - Acute Myeloid Leukemia | Phase 2 | Completed | ASLAN Pharmaceuticals | 24 | 2018-01-05 | 2021-07-06 |
| Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine - Biliary Tract Cancer | Phase 2 | Completed | ASLAN Pharmaceuticals | 62 | 2017-12-19 | 2020-11-19 |
| Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib Varlitinib - Healthy Volunteers | Phase 1 | Completed | ASLAN Pharmaceuticals | 6 | 2017-11-23 | 2018-09-11 |
| Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) Varlitinib, mFOLFOX6, Placebo - Gastric Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 52 | 2017-08-31 | 2022-02-15 |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine, Placebo (for Varlitinib) - Biliary Tract Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 151 | 2017-07-04 | 2021-08-03 |
| A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours varlitinib, capecitabine - Advanced or Metastatic Biliary Tract Cancer, Advanced or Metastatic Solid Tumors | Phase 1 | Completed | ASLAN Pharmaceuticals | 24 | 2017-01-31 | 2018-06-28 |
| Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC Varlitinib, Cisplatin, Gemcitabine - Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | ASLAN Pharmaceuticals | 204 | 2016-12-13 | 2021-01-14 |
| ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy Varlitinib - Cholangiocarcinoma | Phase 2 | Completed | ASLAN Pharmaceuticals | 32 | 2015-11-16 | 2018-05-29 |
| Study of ASLAN001 in Combination With Capecitabine in MBC That Has Failed on Prior Trastuzumab ASLAN001, Lapatinib, Capecitabine - Metastatic Breast Cancer | Phase 2 | Completed | ASLAN Pharmaceuticals | 200 | 2014-12-29 | 2017-10-17 |
| A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects ASLAN003, Matched Placebo - Healthy Elderly Subjects (Age ≥55 Years) | Phase 1 | Completed | ASLAN Pharmaceuticals | 7 | 2014-10-01 | 2016-11-02 |
| Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine ASLAN001, cisplatin + capecitabine, cisplatin + 5-fluorouracil (or+ Leucovorin) - Solid Tumor | Phase 1 | Completed | ASLAN Pharmaceuticals | 31 | 2014-08-05 | 2018-10-25 |
| ASLAN001 in Combination With Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU With Leucovorin ASLAN001+ CAPOX (Oxaliplatin, capecitabine), ASLAN001 + mFolfox6 (5-FU, leucovorin) - Solid Tumors | Phase 1 | Unknown | National Cancer Centre, Singapore | 60 | 2014-08-01 | 2021-04-28 |
| Phase 1, Randomised Double Blinded Placebo Controlled Study of ASLAN003 ASLAN003 ACTIVE - Healthy Volunteers | Phase 1 | Completed | ASLAN Pharmaceuticals | 61 | 2013-08-01 | 2016-11-02 |
| A Phase I Multiple Ascending Dose Study of ASLAN002 in Subjects With Advanced or Metastatic Solid Tumours ASLAN002( BMS 777607) - Malignant Solid Tumour | Phase 1 | Completed | ASLAN Pharmaceuticals | 39 | 2012-10-01 | 2017-01-25 |
Showing 20 of 21. Sign in to see all of them.
Biliary Tract Neoplasms (5) · Dermatitis, Atopic (3) · Bile Duct Neoplasms (2) · Eczema (2) · Gallbladder Neoplasms (2) · Stomach Neoplasms (2) · Alopecia Areata (1) · Breast Neoplasms (1) · Cholangiocarcinoma (1) · Hypersensitivity (1) · Leukemia, Myeloid, Acute (1) · Neoplasms (1)
Capecitabine (7) · ARRY-334543 (4) · Cisplatin (2) · Fluorouracil (2) · Leucovorin (2) · Gemcitabine (1) · Lapatinib (1) · Oxaliplatin (1)
Singapore (12) · South Korea (6) · Taiwan (6) · United States (6) · Australia (5) · Hong Kong (4) · Canada (2) · China (2) · Japan (2) · New Zealand (2) · Poland (2) · Dominican Republic (1) · Estonia (1) · Hungary (1) · India (1)
Matthew CH Ng (1) · Seock-Ah Im, Dr. (1)